The biotech sought to bear this mechanism out in STRIDES, a mid-phase, randomized, double-blinded and placebo-managed demo that evaluated the efficacy and protection of azelaprag—with and without having Eli Lilly’s blockbuster incretin cure tirzepatide—in more than two hundred peop